Detalhe da pesquisa
1.
Paracrine Wnt5a-ß-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.
Immunity
; 48(1): 147-160.e7, 2018 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29343435
2.
Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.
Ann Surg
; 277(6): e1306-e1312, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797609
3.
Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.
Cancer Immunol Immunother
; 70(2): 475-483, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32814992
4.
Role of dendritic cell metabolic reprogramming in tumor immune evasion.
Int Immunol
; 32(7): 485-491, 2020 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449776
5.
Updates in adjuvant systemic therapy for melanoma.
J Surg Oncol
; 119(2): 222-231, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30481375
6.
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.
Sci Immunol
; 9(95): eadi4191, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728412
7.
Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling.
bioRxiv
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38617347
8.
Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.
J Gastrointest Cancer
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133871
9.
A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression.
bioRxiv
; 2023 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37162965
10.
The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice.
Clin Cancer Res
; 29(9): 1670-1677, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920243
11.
Assessing the utility of molecular diagnostic classification for cancers of unknown primary.
Cancer Med
; 12(19): 19394-19405, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712677
12.
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
Nat Med
; 11(2): 130-7, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15665830
13.
The "Inside" Story on Tumor-Expressed PD-L1.
Cancer Res
; 82(11): 2069-2071, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661198
14.
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.
Clin Cancer Res
; 28(1): 13-22, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34312214
15.
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
Sci Transl Med
; 14(672): eabq7019, 2022 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36417489
16.
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
Cancer Immunol Res
; 10(1): 70-86, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795033
17.
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.
J Immunother
; 45(6): 284-290, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35621992
18.
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Clin Cancer Res
; 27(5): 1236-1241, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199494
19.
Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis.
Cancers (Basel)
; 13(19)2021 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638239
20.
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.
Cell Rep
; 35(5): 109071, 2021 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951424